Key Takeaways CANC hit a 52-week high after surging more than 3% on Aug. 19. Moderna's melanoma trial success boosted sentiment across oncology stocks. CANC's positive weighted alpha of 66.73 signals potential for further gains.Tema Oncology ETF (CANC) is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and has surged 72.8% from its 52-week low price of $26.24 per share.Are more gains in store for this ETF? Let us take a quick look at the fund and the near-term outlook ...